title: [A case of gastric cancer in which grade 2 treatment effects were obtained with preoperative two-week S-1 administration].
abstract: In our hospital, a clinical trial on the effects of preoperative 2-week S-1 administration for advanced gastric cancer is being conducted. A7 5-year-old man presented to our hospital with a type 2 tumor(poorly differentiated adenocarcinoma)in the pyloric antrum. Subpyloric lymph node enlargement and a c-T2(MP), N1, M0, Stage II A tumor (according to the gastric cancer handling agreement, 14th edition)were diagnosed, and S-1(100mg/day)was subsequently administered for 14 days. On day 15, we performed laparoscopy-assisted distal gastrectomy, with D2 dissection. Analysis of the resected specimen, ie the primary tumor and metastatic lymph nodes, confirmed the effect of the treatment as Grade 2, and revealed a type 2 gastric cancer of 30×20mm in size; this tumor was downstaged to yp-T1b(SM), N1, Stage I B. No adverse events associated with perioperative S-1 were observed, and the postoperative course was good. At the latest follow-up(6 years after treatment), no recurrence was observed.
authors.affiliation: Dept. of Digestive Surgery, Tokushima Red Cross Hospital.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yuasa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okitsu
authors.forename: Masakazu
authors.initials: M
authors.lastname: Goto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Edagawa
authors.forename: Osamu
authors.initials: O
authors.lastname: Mori
authors.forename: Ryotaro
authors.initials: R
authors.lastname: Tani
authors.forename: Yuri
authors.initials: Y
authors.lastname: Masuda
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kuramoto
authors.forename: Daisuke
authors.initials: D
authors.lastname: Matsumoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tomibayashi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hamada
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamashita
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Fujii
authors.forename: Koji
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D005743:Gastrectomy; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid